Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Julphar
Federal Trade Commission
Accenture
McKinsey
Moodys

Generated: April 25, 2019

DrugPatentWatch Database Preview

TAKEDA Company Profile

« Back to Dashboard

Summary for TAKEDA

Drugs and US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 RX Yes No 7,807,689 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No 9,125,908 ➤ Try a Free Trial ➤ Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 RX Yes Yes 7,361,676 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa ACTOS pioglitazone hydrochloride TABLET;ORAL 021073-003 Jul 15, 1999 6,150,383 ➤ Try a Free Trial
Takeda Pharms Usa ACTOS pioglitazone hydrochloride TABLET;ORAL 021073-001 Jul 15, 1999 4,444,779 ➤ Try a Free Trial
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-002 May 12, 2009 7,919,116 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TAKEDA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 15 mg/1000 mg and 30 mg/1000 mg ➤ Subscribe 2011-09-23
➤ Subscribe Tablets 0.6 mg ➤ Subscribe 2011-12-23
➤ Subscribe Tablets 12.5 mg/500 mg and 12.5 mg/1000 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 8 mg ➤ Subscribe 2009-07-22
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2013-02-13
➤ Subscribe Delayed-release Orally Disinte 15 mg and 30 mg ➤ Subscribe 2006-12-27
➤ Subscribe Delayed-release Capsule 30 mg ➤ Subscribe 2010-11-30
➤ Subscribe Tablets 15 mg/500 mg and 15 mg/850 mg ➤ Subscribe 2008-03-06
➤ Subscribe Tablets 30 mg/2 mg and 30 mg/4 mg ➤ Subscribe 2009-12-22
➤ Subscribe Tablets 6.25 mg, 12.5 mg and 25 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 5 mg, 10 mg, 15 mgand 20 mg ➤ Subscribe 2017-10-02
➤ Subscribe Delayed-release Pellets/Capsul 15 mg and 30 mg ➤ Subscribe 2005-12-05
➤ Subscribe Capsule 60 mg ➤ Subscribe 2010-08-25

Supplementary Protection Certificates for TAKEDA Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1436271 92397 Luxembourg ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE
1586571 2014C/010 Belgium ➤ Try a Free Trial PRODUCT NAME: ALOGLIPTINE (EN TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/844/001 20130923
1436271 2014/022 Ireland ➤ Try a Free Trial PRODUCT NAME: VORTIOXETINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/891 20131220
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKesson
Medtronic
Daiichi Sankyo
Deloitte
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.